There is no cure for Alzheimer’s disease. No drug, supplement, or therapy can reverse or stop the condition once it begins. But the treatment landscape has shifted meaningfully in recent years, with the first drugs that actually slow the disease’s progression now available, and a range of strategies that can reduce risk or manage symptoms at every stage.
Why a Cure Doesn’t Exist Yet
Alzheimer’s isn’t a single malfunction. It involves the buildup of abnormal proteins in the brain (amyloid plaques and tau tangles), widespread inflammation, and the gradual death of neurons across regions responsible for memory, reasoning, and eventually basic body functions. Changes in the brain begin years, sometimes decades, before symptoms appear. By the time someone is diagnosed, significant damage has already occurred.
A true cure would need to halt all of these processes and repair or replace the neurons already lost. Current science can target individual pieces of the puzzle, particularly amyloid plaques, but the downstream damage from tau tangles and inflammation continues even when plaques are cleared. The U.S. government’s 2024 National Plan to Address Alzheimer’s Disease states plainly that without a preventive treatment or cure, the number of Americans with the disease will grow substantially as the population over 85 nearly triples between 2015 and 2050.
Drugs That Slow the Disease
Two FDA-approved treatments now target the underlying biology of Alzheimer’s rather than just masking symptoms. Both are antibody infusions that bind to amyloid plaques and help the brain clear them. They represent the first time medicine has been able to alter the disease’s trajectory, not just treat what it feels like.
In its Phase 3 trial, one of these drugs (donanemab) slowed cognitive and functional decline by roughly 35% and cut the risk of progressing to the next stage of the disease by about 40% over 18 months, in participants with lower levels of tau. Across the full study population, including those with more advanced tau pathology, the slowing was still significant but more modest, around 22 to 29% depending on the measure.
These numbers matter, but they need context. Slowing decline by a third is not the same as stopping it. People on these drugs still get worse over time. The treatments work best in early-stage disease, specifically mild cognitive impairment or mild Alzheimer’s dementia with confirmed amyloid buildup. They have not been shown to help people in moderate or severe stages. They also carry risks, including brain swelling and small brain bleeds that require regular monitoring with MRI scans.
For Medicare coverage, you need a diagnosis of mild cognitive impairment or mild Alzheimer’s with documented amyloid plaques, a physician participating in a qualifying registry, and appropriate follow-up care. Under Original Medicare, you pay 20% coinsurance after meeting your Part B deductible. Supplemental or Medicare Advantage plans may change what you owe.
Medications That Manage Symptoms
Before these newer drugs existed, the only Alzheimer’s medications were purely symptomatic. They remain widely used and can meaningfully improve quality of life even though they don’t change the course of the disease.
One class of drugs works by boosting levels of a chemical messenger in the brain that helps nerve cells communicate. These are typically prescribed for mild to moderate Alzheimer’s. They don’t create new brain cells or stop existing ones from dying, but they help the remaining cells work more efficiently. In clinical trials, withdrawing these drugs in people with moderate to severe disease increased the risk of nursing home placement within 12 months.
A second type of drug, used for moderate to severe stages, works by regulating a different brain signaling system that can become overactive and damage neurons. It’s often combined with the first type. Together, they can help with memory, attention, and the ability to perform daily tasks for a period of time, though their effects are temporary.
What’s in the Research Pipeline
The next frontier is tau. Amyloid plaques appear to trigger the disease, but tau tangles correlate more closely with the actual death of neurons and the severity of symptoms. Several experimental therapies are now targeting tau directly, including antibody treatments and a newer approach that uses short strands of genetic material to reduce tau production at the source.
Early data from these trials show the first signs that tau buildup in the brain can be slowed in humans. That’s a meaningful proof of concept, though the treatments haven’t yet met their primary goals of improving cognition in large trials. They remain in early to mid-stage testing.
Stem cell therapy is also being explored, with early-phase trials currently recruiting participants with early-stage Alzheimer’s. These studies are primarily assessing safety and have not yet produced results. It will likely be years before stem cell approaches are close to clinical use, if they prove effective at all.
Lifestyle Factors That Lower Risk
For people without Alzheimer’s who want to reduce their chances of developing it, the evidence on lifestyle is surprisingly strong. A large study funded by the National Institute on Aging found that people who followed four or five healthy habits had a 60% lower risk of developing Alzheimer’s compared to those who followed none or one. Even adopting two or three of these habits was associated with a 37% reduction in risk.
The five factors studied were:
- Physical activity: at least 150 minutes per week of moderate to vigorous exercise
- Not smoking
- Light to moderate alcohol consumption
- A high-quality diet: specifically the MIND diet, which combines elements of Mediterranean and heart-healthy eating patterns
- Cognitive engagement: activities that challenge the brain in later life, such as reading, puzzles, or learning new skills
These habits don’t guarantee prevention. Genetics play a role, particularly a gene variant called APOE ε4 that increases risk and is associated with earlier onset. Carrying two copies raises risk more than carrying one. But having the gene doesn’t make Alzheimer’s inevitable, and not having it doesn’t make you immune. Genetic testing for APOE is primarily used in research settings to identify study participants, not to predict individual outcomes.
Earlier Detection Is Changing the Picture
One of the biggest practical shifts is in diagnosis. A blood test measuring a specific protein fragment linked to Alzheimer’s pathology now predicts the disease with 88 to 92% accuracy compared to spinal fluid tests or PET brain scans. This matters because amyloid PET scans are expensive, spinal taps are invasive, and both have limited availability. A simple blood draw could make early diagnosis accessible to far more people, which is essential when the most promising treatments only work in the earliest stages.
What This Means for You or Your Family
If you’re looking for a way to reverse Alzheimer’s in someone you love, the honest answer is that it doesn’t exist today. What does exist is a growing set of tools. Disease-modifying drugs can buy time in early stages, symptom-management medications can improve daily functioning, and lifestyle changes can meaningfully lower risk for those not yet affected. The disease typically lasts four to eight years after diagnosis, though some people live 20 years, with the moderate stage often being the longest. Planning for that timeline, both medically and practically, is one of the most useful things a family can do.
The pace of Alzheimer’s research is faster now than at any point in history. The first drugs that touch the disease’s biology were approved only recently. Tau-targeting treatments are producing early proof of concept. Blood-based diagnostics are becoming a reality. None of this is a cure, but the gap between “nothing works” and “something works partially” has already been crossed.